Winter is the season of high incidence of respiratory infectious diseases such as pneumonia. On January 24, Beijing Minhai Technology, a subsidiary of Shenzhen Kangtai Biological Products Co., Ltd., developed by Beijing Minhai Technology, a dual-carrier 13-valent pneumonia vaccine with completely independent intellectual property rights in mainland China, announced in Nanjing that it will be fully listed in Jiangsu Province in the near future. At present, the vaccination clinic of each community health service center can be booked, and the vaccination age is 6 weeks to 5 years old, and the price is 458 yuan / dose.
Pneumococcal disease has been one of the most important public health problems worldwide. The World Health Organization estimates that around 700,000-1 million children under the age of 5 die globally each year from various pneumococcal diseases. Experts say that pneumococcal nature usually has three "1/3": 1/3 of children may be infected with streptococcus pneumoniae, 1/3 of children will die from pneumonia infection, and 1/3 of children will still have sequelae even after cure. To this end, in 2017, WHO listed pneumococcal bacteria as a "deadly drug-resistant bacterium that seriously threatens human health".
According to experts, in the past, the mainland's pneumonia vaccine mainly relied on imports, and it was a "single carrier", the disadvantage of which was that the amount of antigen required was large, and the adverse reaction rate was higher, and the "Weimin Feibao" independently developed by the mainland was the world's first "double carrier" 13-valent vaccine, and the advantage was that it could avoid the competition of single carrier proteins for helper T cells and inhibit the immune response of polysaccharides, which was more efficient, better safety, and could play a multiplier effect with half the effort.
The expert further explained that the "double-carrier" 13-valent pneumonia vaccine phase III clinical trial data showed that the antibody positivity rate and the geometric average titer of antibodies against 13 serotypes of pneumococcal bacteria were better than similar imported products. At the same time, the incidence of adverse reactions in clinical trials was lower than that of the control group products. It is worth mentioning that the dual-carrier 13-valent pneumonia vaccine has a good effect on infants and children aged 6 weeks to 5 years old (before the 6th birthday), which greatly relaxes the time limit for vaccination compared with similar vaccines.
The domestic dual-carrier 13-valent pneumonia vaccine not only breaks through in technology, but also makes the vaccine more than 30% cheaper than imported vaccines in the case of the effectiveness and safety of the vaccine, ensuring that domestic infants and young children can fight and play in the face of pneumococcal invasion.
Experts said that the immune function of children under the age of 6 is not yet fully developed, and they are always facing a huge risk of pneumococcal invasion. The WHO calls for pneumococcal diseases to be a very high priority disease that requires vaccination for prevention, and once infected with pneumococcal diseases, it is very likely to cause serious sequelae such as mental retardation and paralysis. Vaccination with 13-valent pneumonia vaccine can protect children from the invasion of the 13 most common and harmful pathogenic serotypes of pneumococcus, help children establish protective barriers, and is of great significance to the healthy growth of children.